Stoke Therapeutics, Inc.
zorevunersen
Dravet syndrome
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for zorevunersen in Dravet syndrome are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“The Company expects to complete enrollment of 150 patients in the second quarter of 2026, with a data readout in mid-2027 that is anticipated to support the submission of a New Drug Application (an “NDA”) to the U.S. Food and Drug Administr”